InsiderDB

Lobbying disclosures · Lobbying report

GILD: second_quarter 2026 lobbying report

Issues related to healthcare, including improving patient access to advanced immunology therapies; Issues related to policies affecting biopharma products pricing, coverage and access in Medicare and Medicaid; Issues related to funding for HIV and HCV screening, linkage to care and treatment; Issues related to breast cancer screening.

Follow GILD
Became public
Jul 20, 2026, 5:56 PM EDT
Event / period date
Not stated
Collected
Nov 10, 2026, 2:39 PM EST

Why this is connected

Exact legal-name match: GILEAD SCIENCES, INC. (https://www.sec.gov/Archives/edgar/data/882095/).

Reported lobbying amounts

Income: $90,000.00

These are different reporting measures. They are not added together or treated as spending on one particular bill.

Source evidence

Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/28ee5aef-77cb-44e3-b0d2-ae07ba9043b6/","filing_uuid":"28ee5aef-77cb-44e3-b0d2-ae07ba9043b6","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/28ee5aef-77cb-44e3-b0d2-ae07ba9043b6/print/","filing_document_content_type":"text/html","income":"90000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Zachary Williams","dt_posted":"2026-07-20T17:56:06-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"777 6th Street NW","registrant_address_2":"8th Floor","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":400976792,"url":"https://lda.gov/api/v1/registrants/400976792/","house_registrant_id":null,"name":"FORBES-TATE","description":"Government Relations Firm.","address_1":"777 6th Street NW","address_2":"8th Floor","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ZACHARY WILLIAMS","contact_telephone":"+1 202-638-0125","dt_updated":"2026-07-20T16:54:02.529740-04:00"},"client":{"id":205130,"url":"https://lda.gov/api/v1/clients/205130/","client_id":1522,"name":"GILEAD SCIENCES, INC.","general_description":"Specialty biopharmaceutical company.","client_government_entity":false,"client_self_select":null,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-02-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to healthcare, including improving patient access to advanced immunology therapies; Issues related to policies affecting biopharma products pricing, coverage and access in Medicare and Medicaid; Issues related to funding for HIV and HCV screening, linkage to care and treatment; Issues related to breast cancer screening.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":72734,"prefix":null,"prefix_display":null,"first_name":"BARRETT","nickname":null,"middle_name":null,"last_name":"THORNHILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68997,"prefix":null,"prefix_display":null,"first_name":"CYNTHIA","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57902,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"GREER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}

Congressional trading in GILD

These disclosures provide context. Their presence does not establish a link between a trader and the event.

Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.

GILD: second_quarter 2026 lobbying report | InsiderDB